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Background: Pilsicainide, classiﬁed as a relatively selective Naþ channel blocker, also has an inhibitory
action on the rapidly-activating delayed-rectiﬁer Kþ current (IKr) through human ether-a-go-go-related
gene (hERG) channels. We studied the effects of chronic exposure to pilsicainide on the expression of
wild-type (WT) hERG proteins and WT-hERG channel currents, as well as on the expression of mutant
hERG proteins, in a heterologous expression system.
Methods: HEK293 cells stably expressing WT or mutant hERG proteins were subjected to Western
blotting, immunoﬂuorescence microscopy and patch-clamp experiments.
Results: Acute exposure to pilsicainide at 0.03–10 μM inﬂuenced neither the expression of WT-hERG
proteins nor WT-hERG channel currents. Chronic treatment with 0.03–10 μM pilsicainide for 48 h,
however, increased the expression of WT-hERG proteins and channel currents in a concentration-
dependent manner. Chronic treatment with 3 μM pilsicainide for 48 h delayed degradation of WT-hERG
proteins and increased the channels expressed on the plasma membrane. A cell membrane-impermeant
pilsicainide derivative did not inﬂuence the expression of WT-hERG, indicating that pilsicainide stabi-
lized the protein inside the cell. Pilsicainide did not inﬂuence phosphorylation of Akt (protein kinase B)
or expression of heat shock protein families such as HSF-1, hsp70 and hsp90. E4031, a chemical cha-
perone for hERG, abolished the pilsicainide effect on hERG. Chronic treatment with pilsicainide could also
increase the protein expression of trafﬁcking-defective mutant hERG, G601S and R752W.
Conclusions: Pilsicainide penetrates the plasma membrane, stabilizes WT-hERG proteins by acting as a
chemical chaperone, and enhances WT-hERG channel currents. This mechanism could also be applicable
to modulations of certain mutant-hERG proteins.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Human ether-a-go-go-related gene (hERG) encodes the alpha
subunit of the rapidly-activating delayed-rectiﬁer Kþ channel,
which plays a pivotal role in repolarization of cardiac action
potentials (APs) [1]. Most of mutant hERG proteins causing the
type 2 long QT syndrome (LQT2) fail to mature in the endoplasmic
reticulum (ER) and Golgi apparatus [2]. Because of their instability,
they are degraded through the ubiquitin proteasome system (UPS),
resulting in reductions of hERG protein expression on the cell
membrane and channel currents [3].
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A possible way to rescue mutant hERG proteins is the use of a
chemical chaperone, which is deﬁned as a small molecule that can
bind to a protein and stabilize it [4]. Several agents have been
reported to bind to hERG proteins inside the cell and restore their
stability, including hERG activators [5] and hERG blockers [6,7].
HERG channel blockers, such as E4031, fexofenadine and astemi-
zole, facilitated maturation of hERG proteins by acting as chemical
chaperones [8]; however, these agents cannot be used clinically for
enhancing hERG channel currents, because they acutely block the
rapidly-activating delayed-rectiﬁer Kþ channel current (IKr).
Pilsicainide (C17H24N2O) is a widely used antiarrhythmic agent,
especially for treating atrial ﬁbrillation [9]. It belongs to the class Ic
antiarrhythmic agent (Naþ channel blocker) as classiﬁed by
Vaughan Williams [10], reducing the maximum rate of AP
upstroke in atria, ventricles and Purkinje ﬁbers [11]. The effects of
pilsicainide on AP repolarization are controversial: Pilsicainide did
not inﬂuence AP repolarization in rat ventricular myocytes [12].
However, pilsicainide has been reported to block hERG channel
currents expressed in HEK293 cells [13], implying the reduction of
IKr and prolongation of AP duration (APD) by the agent. In contrast,
pilsicainide shortened APDs in canine Purkinje ﬁbers [11] and in
guinea pig ventricular myocardia [14], which might reﬂect the
enhancement of IKr via stabilization of hERG proteins. However, it
remains unknown whether pilsicainide actually stabilizes hERG
proteins. In the present study, we studied the effects of acute and
chronic exposures to pilsicainide on the expression of hERG pro-
teins and found that chronic treatment with pilsicainide as a
chemical chaperon could stabilize hERG proteins in transfected
mammalian cells.
2. Materials and methods
2.1. Cell culture and establishment of HEK293 cell lines stably
expressing WT-hERG and mutant hERG
cDNA encoding the wild-type hERG protein tagged with the
FLAG octapeptide epitope (WT-hERG-FLAG) was cloned in a
mammalian expression vector, pcDNA3.1 (þ) (Invitrogen, Carls-
bad, CA, USA). Individual expression plasmids were transfected
into HEK293 cells using Lipofectamine 2000 (ThermoFisher Sci-
entiﬁc, Waltham, MA, USA) following the manufacturer's instruc-
tions. To establish the cells stably expressing WT-hERG-FLAG, they
were cultured in the presence of 1 mg/mL Geneticin (G418) and
cell clones were then harvested. The expression of WT-hERG-FLAG
was conﬁrmed by Western blotting.
Cells were cultured in Dulbecco's modiﬁed Eagle's medium (D-
MEM; Wako, Osaka, Japan) supplemented with 10% fetal bovine
serum (Nichirei Biosciences, Tokyo, Japan) and 0.5% penicillin-
streptomycin G (Wako, Osaka, Japan) at 37 °C in a 5% CO2 incu-
bator in the presence and absence of pilsicainide at 0.03–10 μM.
We also used HEK293 cells stably expressing mutant hERG
proteins with a mutation of G601S or R752W, both of which are
trafﬁcking-defective. G601S locates in the pore region of hERG
channels, while R752W in the intracellular domain, as described
elsewhere [15].
2.2. Western blotting
Cells were scraped into lysis buffer (PBS/1% NP40, 0.5% sodium
deoxycholate, 0.1% SDS, 10 μg/ml aprotinin, 10 μg/ml leupeptin,
10 μg/ml pepstain, and 1 mM phenylmethylsulfonyl ﬂuoride) and
lysed by sonication; insoluble materials were then removed by
centrifugation. Protein concentrations were determined with a
protein assay kit (Bio-Rad, Hercules, CA, USA). Ten μg of proteins
was separated on 7.5% SDS-PAGE and electrotransferred to a
polyvinylidene diﬂuoride (PVDF) membrane (Immobilon-P, Milli-
pore, Bedford, MA, USA). Membranes were probed with antibodies
against FLAG (1:1000; Agilent Technologies, Santa Clara, CA, USA),
β-actin (1:5000; Abcam, Tokyo, Japan), total and phosphorylated
Akt (protein kinase B) (1:1000; Enzo Life Sciences, NY, USA), and
heat shock protein (hsp) families of the heat shock factor 1 (HSF-
1), hsp70 and hsp90 (1:1000; Enzo Life Sciences, NY, USA), and
were developed using an enhanced chemiluminescence (ECL)
system (Amersham, Piscataway, NJ, USA). Band intensities were
quantiﬁed using Image J software (NIH, Bethesda, MD, USA). To
determine the half-maximal effective concentration (EC50) of pil-
sicainide for the increase of hERG proteins, concentration depen-
dence data were ﬁtted by the following equation:
D¼ Dmax100ð Þ  C½ = C½ þEC50ð Þþ100; ð1Þ
where D (%) represents the normalized hERG protein density at a
given concentration ([C]). Dmax (%) denotes the maximum attain-
able density.
2.3. Chase assay
HEK293 cells stably expressing WT-hERG-FLAG were seeded
into 6-well plates in the presence or absence of pilsicainide at
3 μM. After the addition of the protein synthesis inhibitor cyclo-
heximide (60 μg/ml), protein extracts were prepared at 2–24 h
and subjected to anti-FLAG Western blotting. Band intensity was
quantiﬁed using the Image J software. The decay rate constant (k)
for the density of expressed WT-hERG-FLAG proteins was deter-
mined using OriginPro 9.1 (Origin Lab, Northampton, MA, USA).
The half-life (t1/2) of the protein was calculated using the formula
t1/2¼0.693/k.
2.4. Immunoﬂuorescence
HEK293 cells stably expressing WT-hERG-FLAG were seeded on
gelatin-coated coverslips and transfected with pDsRed2-ER
(Clontech, Mountain View, CA, USA), pDsRed-Monomer-Golgi
(Clontech) or pPM-mKeima-Red (BML, Tokyo, Japan). Twenty-
four hour later, they were ﬁxed with 4% paraformaldehyde/PBS
and then permealized with 0.5% Triton X-100. After blocking in 3%
albumin solution diluted with PBS containing 0.5% Triton X-100,
they were incubated for 1 h with anti-FLAG antibody (1:200;
Agilent Technologies, Santa Clara, CA, USA). Bound antibodies
were visualized with Alexa Fluor 488-conjugated mouse second-
ary antibody (1:2000; Invitrogen, Eugene, OR, USA) and images
were obtained by using a Bio-Rad MRC 1024 confocal microscope
(Hercules, CA, USA). All the staining procedures were conducted at
room temperature in the presence or absence of pilsicainide at
3 μM.
2.5. Electrophysiological recordings
WT-hERG channel currents were recorded by the whole-cell
patch-clamp technique. The extracellular solution had the fol-
lowing composition (mM): NaCl 140, KCl 4, CaCl2 1.8, MgCl2 0.53,
NaH2PO4 0.33, glucose 5.5, HEPES 5, with pH adjusted to 7.4 by
NaOH. The internal pipette solution contained (mM) K-aspartate
100, KCl 20, CaCl2 1, Mg-ATP 5, EGTA 5, HEPES 5, and creatine
phosphate dipotassium salt 5 (pH 7.2 with KOH). Patch pipettes
had a resistance of 2–4 MΩ when ﬁlled with the pipette solution.
After rupture of the cell membrane, whole-cell membrane cur-
rents were recorded at 37 °C with a holding potential (HP) of
50 mV. Series resistance (Rs) was determined by ﬁtting a single
exponential function to the capacitive current decay to estimate its
time constant (τ) and membrane capacitance (Cm); Rs calculated
with the equation Rs¼τ/Cm during the capacitive current
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cancellation averaged 2.270.4 MΩ with τ¼9878 μs and
Cm¼4672 4 pF (n¼5). After 50–60% compensation of Rs, voltage
errors arising from the Rs were estimated to be less than 5 mV. The
membrane potential was not corrected for the liquid junction
potential, which was estimated to be o10 mV. Currents were
elicited by 300-ms depolarizing test pulses ranging from 50 to
þ50 mV (in 10 mV increments). To isolate hERG channel currents,
E4031, a blocker selective for hERG channels, was added at 10 μM
to the external solution; E4031-sensitive currents were deter-
mined by digital subtraction of the currents recorded in the pre-
sence of 10 μM E4031 from those recorded without E4031. The
peak currents during the depolarizing test pulses were measured
and plotted as functions of the test potentials.
2.6. Synthesis of membrane-impermeant pilsicainide
Commercial pilsicainide (Sigma Aldrich, Tokyo, Japan) was
provided as a hydrochloric salt (pilsicainide-HCl); this form is
immediately converted to the non-protonic form (pilsicainide)
in vivo (Supplemental Fig. S1, top), incorporated into the target cell
through the cell membrane, and then performs various actions.
We envisioned that a membrane-impermeant pilsicainide analo-
gue might be useful to determine the origin of its physiological
actions, and thus turned our attention to the methylsulfate of N-
methylpilsicainide (N-Me-PIL-MeSO4) which has the same struc-
tural motif as pilsicainide. This analogue cannot be converted to
the original molecule (pilsicainide) even if it is treated with a
strong base, although the counter anion could be changeable
(Supplemental Fig. S1, bottom). Therefore, it is expected that
pilsicainide-HCl and N-Me-PIL-MeSO4 should show completely
different cell membrane permeant properties: The former can pass
through the cell membrane freely; the latter cannot pass, because
a positively-charged compound should be trapped by the
negatively-charged lipid phosphate moiety in the cell membrane.
Thus, we decided to prepare N-Me-PIL-MeSO4 as a model com-
pound for the membrane-impermeant pilsicainide analogue in
this study. For the details of the synthesis, see Supporting
Information.
2.7. Qualitative RT-PCR
Total RNAs were extracted from HEK293 cells using an RNeasy
Plus mini kit (QIAGEN, Tokyo, Japan) and were then subjected to
RT-PCR assays using PrimeScrips RT-PCR Kit (Takara, Kusatsu,
Japan). RNA samples were treated with DNase I (Promega, Tokyo,
Japan) to eliminate genomic DNA, and cDNA was synthesized
using SuperScriptTM II reverse transcriptase (Thermo Fisher Sci-
entiﬁc, Yokohama, Japan). Primers used were as follows: hERG
forward primer, GGGCTCCATCGAGATCCT; hERG reverse primer,
AGGCCTTGCATACAGGTTCA; GAPDH forward primer, TGAACGG-
GAAGCTCACTGG; GAPDH reverse primer, TCCACCACCCTGTTGCT
GTA.
2.8. Statistical analysis
All data were presented as mean7SEM, and were analyzed
using Student t-test to compare treated and untreated groups. The
differences between the groups were considered signiﬁcant at
Po0.05.
3. Results
3.1. Acute effects of pilsicainide on the expression of WT-HERG
proteins and channel currents
Fig. 1A shows the acute effects of pilsicainide on the hERG
protein expression in HEK293 cells stably expressing WT-hERG.
Treatment with pilsicainide at 0.03–10 μM for 10 min inﬂuenced
neither the expression level of the mature form (155 kDa) nor that
of the immature form (135 kDa). We also examined the effects of
10 min perfusions of pilsicainide at 3 μM on WT-hERG channel
currents in HEK293 cells stably expressing WT-hERG (Fig. 1B).
Acute exposure to 3 μM pilsicainide did not signiﬁcantly inﬂuence
the peak amplitude of hERG currents.
3.2. Chronic effects of pilsicainide on the expression of WT-hERG
proteins and channel currents
Fig. 2A shows effects of the chronic exposure to pilsicainide for
48 h on the expression of WT-hERG proteins in HEK293 cells
stably expressing WT-hERG. Pilsicainide at 0.03–10 μM increased
the mature form (155 kDa) of WT-HERG proteins as well as the
immature form (135 kDa) in a concentration-dependent manner.
The EC50 value for the pilsicainide-induced increase of the
immature form of hERG was 0.33 μM. As shown in Supplemental
Fig. S2, pilsicainide at 3 μM did not inﬂuence the expression of
hERG mRNA.
We further studied the effects of chronic treatment with pil-
sicainide at 3 μM on the E4031-sensitive WT-hERG current
(Fig. 2B). Chronic treatment with 3 μM pilsicainide for 48 h sig-
niﬁcantly increased E4031-sensitive currents. The current-voltage
relationships for E4031-sensitive peak currents indicate that the
chronic treatment with 3 μM pilsicainide signiﬁcantly increased
the peak amplitude of WT-hERG channel currents at the test
potentials ranging from 0 mV to þ40 mV.
3.3. Chronic effects of pilsicainide on degradation of WT-hERG
proteins
To clarify effects of chronic treatment with pilsicainide on the
stability of WT-hERG proteins, we examined WT-hERG protein
degradation by the chase experiments. In the absence of pilsicai-
nide, the immature form of WT-hERG proteins was degraded with
the half-life of 4.970.8 h, as shown in Fig. 3A (left) and B. Treat-
ment with 3 μM pilsicainide for 48 h signiﬁcantly slowed the
degradation process (Fig. 3A, right), prolonging the half-life of the
immature form to 8.970.8 h (Fig. 3B).
3.4. Chronic effects of pilsicainide on the intracellular localization of
WT-hERG proteins
Fig. 4 shows the intracellular localization of WT-hERG proteins
in the absence and presence of pilsicainide at 3 μM. Immuno-
ﬂuorescence demonstrated that the signals of WT-hERG-FLAG co-
localized with those of the ER, Golgi apparatus and plasma
membrane (PM), as depicted by DsRed2-ER (#1–3), DsRed-
Monomer-Golgi (#7–9), and PM-mKeima-Red (#13–15), respec-
tively. In the presence of pilsicainide, the signal of WT-hERG-FLAG
signiﬁcantly increased in the ER (#4–6), Golgi apparatus (#10–12)
and PM (#16–18).
3.5. Failure of a membrane-impermeant pilsicainide derivative to
stabilize WT-hERG
Fig. 5 shows the effects of the cell membrane-impermeant form
of pilsicainide (N-Me-PIL-MeSO4) on the expression of WT-hERG.
T. Onohara et al. / Journal of Arrhythmia ∎ (∎∎∎∎) ∎∎∎–∎∎∎ 3
Please cite this article as: Onohara T, et al. Molecular mechanisms underlying the pilsicainide-induced stabilization of hERG proteins in
transfected mammalian cells. J Arrhythmia (2016), http://dx.doi.org/10.1016/j.joa.2016.09.003i
Chronic treatment with this form of pilsicainide failed to increase
the protein level of WT-hERG.
3.6. Pilsicainide inﬂuenced neither phosphorylation of Akt nor the
expression levels of hsp family proteins
Since it has been reported that antiarrhythmic agents could
modulate ion channel activity via activation of the Akt signal, we
tested whether pilsicainide could inﬂuence phosphorylation of
Akt. As shown in Fig. 6A, LY294002, a PI3-kinase inhibitor, abol-
ished phosphorylation of Akt without changing the total expres-
sion of Akt, but did not affect the expression of WT-hERG. Pilsi-
cainide at 3 μM, not inﬂuencing phosphorylation of Akt, increased
the protein level of WT-hERG even in the presence of LY294002.
It is also known that HSF-1, hsp70 and hsp90 could stabilize
WT-hERG proteins [15]; therefore, we tested whether pilsicainide
would increase the expressions of these regulatory proteins.
Fig. 6B shows the effects of pilsicainide on the expressions of HSF-
1, hsp70 and hsp90 as well as WT-hERG-FLAG proteins. Pilsicai-
nide at 3 μM increased the expression levels of WT-hERG without
enhancing the expression of HSF-1, hsp70 or hsp90.
3.7. Chronic effects of pilsicainide on WT-hERG expressions in the
presence of E4031
It has been reported that E4031 increases hERG expression
levels via an action as a chemical chaperone [7]. To determine
whether pilsicainide could also enhance the expression of WT-
hERG by acting as a chemical chaperone, we examined the effects
of pilsicainide on WT-hERG expression levels in the presence of
E4031. As shown in Fig. 7, 10 μM E4031 as well as 3 μM pilsicai-
nide increased WT-hERG expression levels, as expected. However,
in the presence of E4031, pilsicainide could not further enhance
WT-hERG expressions.
3.8. Chronic effects of pilsicainide on the trafﬁcking-defective mutant
hERG expression
It is important to test whether pilsicainide can stabilize
trafﬁcking-defective mutant hERG proteins observed in LQT2
patients. As shown in Fig. 8, therefore, we examined the effects of
pilsicainide on the expressions of two trafﬁcking-defective mutant
hERG proteins, G601S and R752W. Pilsicainide at 1 and 3 μM
obviously increased the immature form (135 kDa) of G601S and
also slightly increased the mature form (155 kDa). By contrast,
pilsicainide at 3 and 10 μM increased the immature form of
R752W without changes in its mature form.
4. Discussion
In the present study, chronic treatment with pilsicainide sta-
bilized WT-hERG proteins, increased WT-hERG channels in the
plasma membrane, and thereby enhanced the hERG channel cur-
rent IKr. Pilsicainide exerted these effects inside the cell via an
action as a chemical chaperone, independently of phosphorylation
of Akt and enhanced expression of HSF-1, hsp70 or hsp90.
Pilsicainide is a class Ic antiarrhythmic agent that blocks Naþ
channels and reduces the maximum rate of AP upstroke. Pilsicai-
nide occasionally caused QT prolongation, suggesting its inhibitory
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Fig. 1. Acute effects of pilsicainide on the expression of WT-hERG proteins and channel currents. (A) Effects of 10 min application of pilsicainide at 0.03–10 μM on WT-hERG
protein expressions. Representative Western blots show bands of hERG proteins at 135 kDa (immature form) and 155 kDa (mature form) with those of β-actin being used for
normalizing the band density of hERG proteins (left). The density of the immature and mature forms of hERG proteins determined at each concentration of the agent was
normalized ﬁrst to that of β-actin and then to that of WT-hERG-FLAG in the absence of pilsicainide (right; n¼4 each). (B) Effects of 10 min application of pilsicainide on hERG
channel currents. Shown are representative traces of E4031-sensitive hERG channel currents recorded in HEK293 cells expressing WT-hERG-FLAG in the absence (Control)
and presence of pilsicainide at 3 μM (left). Current–voltage relationships were determined for WT-hERG-FLAG protein-mediated peak currents during the depolarizing test
pulses (right; n¼10 each). Error bars smaller than the radius of the circles are not shown.
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Fig. 2. Chronic effects of pilsicainide on the expression of WT-hERG proteins and channel currents. (A) Representative Western blots for WT-hERG-FLAG proteins expressed
with or without pilsicainide (left). Cells stably expressing WT-hERG were exposed to pilsicainide at 0.03–10 μM for 48 h. Cell lysates were subjected to Western blotting with
anti-FLAG and anti-β-actin antibodies. Two bands for the mature form of 155 kDa and immature form of 135 kDa were observed. The band density of WT-hERG-FLAG
proteins was quantiﬁed as a ratio to that of β-actin, and was then normalized to that of WT-hERG-FLAG in the absence of pilsicainide (right). Differences were tested for
statistical signiﬁcance by two-way ANOVA: *Po0.05 vs. Control (0) (n¼10 each). (B) Representative traces of E4031-sensesitive hERG channel currents recorded from
HEK293 cells treated with or without pilsicainide at 3 μM for 48 h (left). Current-voltage relationships were determined for WT-hERG-FLAG protein-mediated peak currents
during the depolarizing test pulses in the absence and presence of pilsicainide (right; n¼10 each). Differences were tested for statistical signiﬁcance by two-way ANOVA:
*Po0.05 vs. Control. Error bars smaller than the radius of the circles are not shown.
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Fig. 3. Chronic effects of pilsicainide on the degradation of WT-hERG proteins. (A) Representative Western blots of residual WT-hERG proteins at 0–24 h after treatment with
cycloheximide in the absence (Control) and presence of pilsicainide. Cells in the pilsicainide-treated group were exposed to 3 μM pilsicainide for 48 h prior to the treatment
with cycloheximide. (B) Decay of WT-hERG proteins in the absence (Control) and presence of 3 μM pilsicainide. The amount of expressed hERG-FLAG was quantiﬁed as a ratio
to that of β-actin, and was then normalized to that at time¼0. The lines are the ﬁts with a single exponential function. *Po0.05, vs. Control (n¼3 each).
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action on outward Kþ currents. Wu et al. have reported that,
although pilsicainide barely affected Kþ and Ca2þ currents at
therapeutic concentrations of 0.20–0.90 μg/mL (0.73–3.31 μM), it
blocked hERG channel currents at concentrations higher than the
therapeutic range [13]. In the present study, chronic treatment
with pilsicainide at therapeutic concentrations signiﬁcantly
increased WT-hERG protein expressions via the prolongation of
the half-life of WT-hERG proteins and thereby enhanced hERG
channel currents, whereas acute treatment with pilsicainide at
10 μM or less inﬂuenced neither hERG protein expressions nor
channel currents. Thus, while pilsicainide has been observed to
cause QT prolongation occasionally, it can also shorten QT intervals
by enhancing IKr.
It is well known that Naþ channel blockers bind to the Naþ
channel from inside of the cell but the charged form blocker
cannot penetrate the plasma membrane [16]. In the present study,
the membrane-impermeant form of pilsicainide (N-Me-PIL-
MeSO4) did not increase the protein level of WT-hERG, suggesting
that pilsicainide normally penetrates the plasma membrane and
induces post-translational modiﬁcations of the WT-hERG protein.
Pilsicainide might increase hERG proteins via facilitating the
transcription of hERG from DNA to RNA or the translation of hERG
RNA into hERG protein. Qualitative RT-PCR demonstrated the
absence of an increase in hERG mRNA expression levels after pil-
sicainide treatment (Supplemental Fig. S2), indicating that pilsi-
cainide does not inﬂuence hERG transcription. Inhibition of the
pilsicainide effect by E4031, a known chemical chaperon for hERG,
suggests post-translational modiﬁcations, rather than accelerated
translation, for the pilsicainide effect. Nevertheless, further
experiments are necessary to conﬁrm post-translational mod-
iﬁcations by pilsicainide.
Chronic treatment with antiarrhythmic agents could induce
post-translational modiﬁcations of ion channels and exert pro-
and anti-arrhythmic actions, independent of their acute actions on
ion channels. For instance, some antiarrhythmic agents could
modify Naþ channel activities via phosphorylation of Akt [17].
Phosphorylated Akt is well known to increase hERG channel cur-
rents [18]. In this study, however, chronic exposure to pilsicainide
signiﬁcantly enhanced the expression of WT-hERG proteins
without phosphorylating Akt.
It has been reported that HSF-1, hsp70 and hsp90 increase both
the mature and immature forms of WT and mutant hERG proteins,
and also facilitate the maturation of mutant hERG proteins [15].
Local anesthetics induced hsp70 expression [19]; thus, pilsicainide
may exert its effects via modulating these regulatory proteins. In
the present study, however, pilsicainide did not inﬂuence the
expression of HSF-1, hsp70 or hsp90, excluding the involvement of
these regulators in the pilsicainide-induced enhancement of WT-
hERG protein expressions.
The most prominent ﬁnding of this study is that pretreatment
with E4031 abolishes the enhancement of WT-hERG protein
expression by pilsicainide. Since E4031 is well known to increase
WT-hERG protein levels as a chemical chaperone, the present
ﬁnding suggests that pilsicainide acts on WT-hERG proteins as a
chemical chaperone, like E4031. There are three possible
mechanisms for the pilsicainide-induced increase of hERG proteins
via post-translational modiﬁcations: (1) phosphorylation of Akt,
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Fig. 4. Effects of pilsicainide on the intracellular localization of WT-hHERG-FLAG proteins. Representative immunoﬂuorescence images obtained by a confocal microscope
are shown for the WT-hERG-FLAG protein and DsRed2-ER (top), DsRed-Monomer-Golgi (middle) or PM-mKeima-Red (bottom). Cells stably expressing WT-hERG-FLAG
proteins were transfected with pDsRed2-ER, pDsRed-Monomer-Golgi or pPM-mKeima-Red, and were stained with anti-FLAG and anti-marker antibodies.
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Fig. 5. Effect of membrane-impermeant pilsicainide (N-Me-PIL-MeSO4) on protein
expression of hERG. Representative Western blots are shown for WT-hERG-FLAG
proteins expressed in the cells with or without the membrane-impermeant pilsi-
cainide at 0.03–10 μM. Cells stably expressing WT-hERG were exposed to pilsicai-
nide at indicated concentrations for 48 h.
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(2) activation of hsp expressions, and (3) direct action as a che-
mical chaperone. Involvements of the Akt and hsp pathways have
been denied by our experiments (Fig. 6). A chemical chaperone is
deﬁned as a chemical agent that binds to a target protein, stabi-
lizes its structure, and delays its degradation. In our study, pilsi-
cainide prolonged the half-life of hERG proteins, and the chemical
chaperone E4031 canceled the enhancement of hERG protein
expression by pilsicainide. Taken together, we conclude that pil-
sicainide acts as a chemical chaperone to increase hERG proteins
with facilitation of their maturation.
Chronic treatment with pilsicainide at 0.03–10 μM could sta-
bilize WT-hERG proteins. The minimum effective concentration of
pilsicainide for the action as a chemical chaperone was 0.3 μM,
which is far less than its therapeutic plasma concentrations of
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Fig. 6. Effects of pilsicainide on phosphorylation of Akt and expressions of hsp family proteins. (A) Representative Western blots for WT-hERG-FLAG, phosphorylated Akt (p-
Akt), total Akt and β-actin in cells treated with or without pilsicainide in the absence and presence of the PI3-kinase inhibitor LY294002. Cells stably expressing WT-hERG
were exposed to 3 μM pilsicainide for 48 h. (B) Representative Western blots for WT-hERG-FLAG, HSF-1, hsp70, hsp90 and β-actin in the cells treated with or without
pilsicainide. Cells stably expressing WT-hERG were exposed to 3 μM pilsicainide for 48 h.
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Fig. 7. Treatment with E4031 abolished the pilsicainide-induced increases in protein expression of WT-hERG. (A) Representative Western blots for WT-hERG-FLAG and β-
actin in cells treated with or without pilsicainide in the presence and absence of 10 μM E4031. Cells stably expressing WT-hERG were exposed to 3 μM pilsicainide for 48 h.
(B) Summary of the effects of pilsicainide on the mature (155 kDa) and immature (135 kDa) forms of WT-hERG-FLAG proteins in the presence of absence of 10 μM E4031. The
amount of expressed WT-hERG-FLAG proteins was quantiﬁed as a ratio to that of β-actin, and was then normalized to that of WT-hERG-FLAG in the absence of the agents
(Control). *Po0.05 vs. Control (n¼5 each).
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Fig. 8. Concentration-dependent effects of pilsicainide on the protein expression of the hERG mutants G601S and R752W in transfected HEK293 cells. Cells stably expressing
G601S or R752W mutants were exposed to pilsicainide at 0.03–10 μM for 48 h. Cell lysates were subjected to Western blotting with the indicated antibodies.
T. Onohara et al. / Journal of Arrhythmia ∎ (∎∎∎∎) ∎∎∎–∎∎∎ 7
Please cite this article as: Onohara T, et al. Molecular mechanisms underlying the pilsicainide-induced stabilization of hERG proteins in
transfected mammalian cells. J Arrhythmia (2016), http://dx.doi.org/10.1016/j.joa.2016.09.003i
around 3 μM [20]. The clinical relevance of the enhancing effects
of pilsicainide on WT-hERG expression is clear; chronic treatment
with pilsicainide could shorten the ventricular APD, because hERG
channels are expressed predominantly in ventricular myocytes
and signiﬁcantly contribute to ventricular AP repolarization [1].
Thus, pilsicainide as a chemical chaperone will suppress early
afterdepolarizations by increasing mutant hERG proteins and IKr in
LQTS cardiomyocytes [21]. Augmentation of IKr results in a short-
ening of APDs and a reduction of Ca2þ load in ventricular muscles,
and might also suppress ventricular arrhythmias [20]. However,
one limitation of this study is that our experiments were per-
formed on the heterologous system of HEK293 cells but not on
cardiomyocytes; thus, it is difﬁcult to apply our ﬁndings directly to
the heart. Further experiments will be necessary to conﬁrm
whether pilsicainide can increase hERG proteins and channel
currents in cardiac myocytes.
It is important to know whether pilsicainide can be used as a
therapeutic agent for LQT2 patients; and if so, we should deter-
mine the types of LQT2 mutation carriers to whom pilsicainide
could be administered. As shown in Fig. 8, we examined the effects
of pilsicainide on two mutant hERG proteins, G601S and R752W,
both of which are trafﬁcking-defective. G601S locates in the pore
region of hERG channels, while R752W in the intracellular domain.
Pilsicainide at the clinical concentrations could facilitate the
maturation of hERG channel proteins with the mutations in the
pore region and in the intracellular domain; however, further
experiments are necessary to determine which LQT2 mutation
carriers will receive therapeutic beneﬁts from pilsicainide.
5. Conclusion
Chronic treatment with 0.03–10 μM pilsicainide for 48 h
enhanced the expression of WT-hERG proteins via delaying their
degradation, increasing hERG channel expression and activity on
the plasma membrane. Pilsicainide penetrates the plasma mem-
brane, stabilizes WT-hERG proteins by acting as a chemical cha-
perone, and enhances WT-hERG channel currents without inﬂu-
encing phosphorylation of Akt or expressions of hsp family pro-
teins. This mechanism may also be applicable to modulations of
trafﬁcking-defective mutant hERG proteins.
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